The PCSK5 antibody is a research tool targeting proprotein convertase subtilisin/kexin type 5 (PCSK5), a member of the proprotein convertase family responsible for proteolytic activation of precursor proteins. PCSK5. also known as PC5/6. plays critical roles in cleaving inactive proproteins into biologically active forms, including growth factors, hormones, and receptors. It exists in two isoforms (PC5A and PC5B) with distinct cellular localizations and functions, influencing processes like embryonic development, lipid metabolism, and viral entry (e.g., SARS-CoV-2). Dysregulation of PCSK5 is linked to cancers, cardiovascular diseases, and metabolic disorders, making it a potential therapeutic target.
PCSK5 antibodies are widely used to study its expression, localization, and molecular interactions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Both monoclonal and polyclonal variants exist, with monoclonal antibodies offering higher specificity for specific isoforms or domains (e.g., catalytic or regulatory regions). Challenges include cross-reactivity with other convertases (e.g., PCSK3/Furin) due to structural similarities, necessitating rigorous validation. Recent studies focus on PCSK5's role in tumor progression and its interaction with extracellular matrix components, driving demand for reliable antibodies. Commercial availability from multiple biotech vendors supports diverse research applications, from basic biology to drug discovery.